Find clinical trials for Breast Cancer in Austin, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer

Non-Small-Cell Lung Carcinoma

Neoplasm Metastasis

Ovarian Cancer

Cancer

Colorectal Cancer

Squamous Cell Carcinoma of Head and Neck

Breast Cancer trials near Austin, TX, USA:

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...

Enrolling

Breast Cancer

Breast Neoplasm

Drug: Cyclophosphamide

Drug: Interferon infiltration of the inoculation site

Phase 3

BriaCell Therapeutics

New Braunfels, Texas, United States and 78 other locations

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast...

Enrolling

HR+ HER2- Breast Cancer

Drug: Sapanisertib

Drug: Serabelisib

Phase 1, Phase 2

Faeth Therapeutics

Austin, Texas, United States and 6 other locations

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer....

Enrolling

Metastatic Breast Cancer

Advanced Breast Cancer

Drug: Endocrine Therapy

Drug: Trastuzumab deruxtecan

Phase 3

Daiichi Sankyo

New Braunfels, Texas, United States and 4 other locations

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine ...

Active, not recruiting

Advanced or Metastatic Breast Cancer

Drug: Trastuzumab deruxtecan

Drug: Capecitabine

Phase 3

AstraZeneca

Austin, Texas, United States and 292 other locations

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer...

Active, not recruiting

Breast Cancer

Other: Placebo

Drug: Letrozole

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Austin, Texas, United States and 805 other locations

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)

endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast...

Enrolling

Breast Cancer

Drug: Elacestrant

Drug: Tamoxifen

Phase 3

Stemline Therapeutics

New Braunfels, Texas, United States and 567 other locations

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The...

Invitation-only

Breast Cancer

Drug: Exemestane Tablets

Drug: Anastrozole Tablets

Phase 3

Tolmar Pharmaceuticals

Austin, Texas, United States and 48 other locations

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (FourLight-3)

ribociclib or abemaciclib with letrozole) in people with breast cancer:* HR-positive (breast cancer cells that ne...

Active, not recruiting

Breast Cancer

Drug: PF-07220060

Drug: letrozole

Phase 3

Pfizer

Round Rock, Texas, United States and 459 other locations

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurren...

Active, not recruiting

Breast Cancer, Early Breast Cancer

Drug: Exemestane

Drug: Letrozole

Phase 3

AstraZeneca

Austin, Texas, United States and 660 other locations

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.HR-positive breast cancer cells have...

Enrolling

Breast Cancer

Drug: Fulvestrant

Drug: Exemestane

Phase 3

Pfizer

Austin, Texas, United States and 427 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Breast Cancer in .css-epvm6{white-space:nowrap;}Austin, TX

Related conditions:

Breast Cancer trials near Austin, TX, USA:

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (FourLight-3)

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Find clinical trials for Breast Cancer in Austin, TX